May 2022 tender notification
Pharmac is pleased to provide the latest tender results.
CORRECTION to May 2022 Tender Notification
The May 2022 tender notification notified the incorrect Principal Supply dates for ‘atazanavir sulphate – cap 150 mg’ and ‘atazanavir sulphate – cap 200 mg”.
The May 2022 tender notification also notified the incorrect pack type for ‘atazanavir sulphate – cap 150 mg’
Corrections in bold and strikethrough below.
Download the tender notification [PDF 99 KB]
Tender results
Pharmac has resolved to award tenders for:
- Principal Supply Status for some products included in the 2021/22 Invitation to Tender, dated 1 November 2021;
- Principal Supply Status for some products included in the 2020/21 Invitation to Tender, dated 2 November 2020; and
- Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2019/20 Invitation to Tender dated 1 November 2019.
Some of the pharmaceuticals that will be delisted when the period of Principal Supply Status commences may be subject to existing listing contracts with Pharmac. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts. Pharmac will continue to subsidise those pharmaceuticals accordingly until such time as those pharmaceuticals are delisted.
Notification of Product Changes (NOPC) forms, Containered Trade Product Pack (CTPP) codes and Pharmacodes
Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to submit a Notification of Product Changes (NOPC) form to Pharmac, the Pharmacy Guild and the NZULM by:
- For new listings, by 4pm on 12 June 2022 or the 5th of the month prior to listing, whichever is earlier
- For price changes, by 4pm on the 12th of the month prior to the date of subsidy change
Pharmac cannot list a product (and pharmacies cannot claim) without this information.
More information about this process and NOPC forms can be found on our website.
Suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand(external link) and that a CTPP code has been obtained from the New Zealand Universal List of Medicines(external link).
Pharmacodes and CTPP codes must be provided to Pharmac by the 5th of the month prior to the date of listing, or 10 business days following the market notification date (whichever is earliest).
Pharmac cannot list a product (and pharmacies cannot claim) without the correct Pharmacode.
2019/20 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2023
Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule
1. Tenders awarded to Pharmaceuticals where at least one other brand is listed.
The decisions were as follows:
|
Chemical name |
Presentation; |
Current |
New |
Sole supply Brand |
Date of listing |
Sole Subsidised Supply date |
Brand |
|---|---|---|---|---|---|---|---|
|
Erlotinib hydrochloride |
Tab 100 mg; 30 tablet blister pack |
$764.00 |
$329.70 |
Alchemy (Alchemy) |
1 September 2022 |
1 February 2023 |
Tarceva (Roche) |
|
Erlotinib hydrochloride |
Tab 150 mg; 30 tablet blister pack |
$1146.00 |
$569.70 |
Alchemy (Alchemy) |
1 September 2022 |
1 February 2023 |
Tarceva (Roche) |
Hospital pharmaceutical tenders – Part II of Section H of the Pharmaceutical Schedule
2. Tenders awarded to pharmaceuticals where at least one other brand is listed.
The decisions were as follows:
|
Chemical name |
Presentation; |
Current pack price |
New pack price |
Hospital Supply |
DV Limit |
Listing date |
Hospital Supply Status date |
Brand |
|---|---|---|---|---|---|---|---|---|
|
Erlotinib hydrochloride |
Tab 100 mg; 30 tablet blister pack |
$764.00 |
$329.70 |
Alchemy (Alchemy) |
1% |
1 September 2022 |
1 February 2023 |
Tarceva (Roche) |
|
Erlotinib hydrochloride |
Tab 150 mg; 30 tablet blister pack |
$1146.00 |
$569.70 |
Alchemy (Alchemy) |
1% |
1 September 2022 |
1 February 2023 |
Tarceva (Roche) |
2020/21 Tender – Principal Supply Status applies until 30 June 2024
Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule
3. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.
The decisions were as follows:
|
Chemical name |
Presentation; |
Current |
New |
Principal Supply brand (Supplier) |
Date of listing |
Principal Supply Status date |
|---|---|---|---|---|---|---|
|
Nitrofurantoin |
Tab 50 mg; 100 tablet bottle |
$22.20 |
$22.20 |
Nifuran (W M Bamford & Co) |
1 July 2022 |
1 December 2022 |
|
Nitrofurantoin |
Tab 100 mg; 100 tablet bottle |
$37.50 |
$37.50 |
Nifuran (W M Bamford & Co) |
1 July 2022 |
1 December 2022 |
Hospital pharmaceutical tenders – Part II of Section H of the Pharmaceutical Schedule
4. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.
The decisions were as follows:
|
Chemical name |
Presentation; |
Current |
New |
Principal Supply brand (Supplier) |
DV limit |
Date of listing |
Principal Supply Status date |
|---|---|---|---|---|---|---|---|
|
Nitrofurantoin |
Tab 50 mg; 100 tablet bottle |
$22.20 |
$22.20 |
Nifuran (W M Bamford & Co) |
5% |
1 July 2022 |
1 December 2022 |
|
Nitrofurantoin |
Tab 100 mg; 100 tablet bottle |
$37.50 |
$37.50 |
Nifuran (W M Bamford & Co) |
5% |
1 July 2022 |
1 December 2022 |
2021/22 Tender – Principal Supply Status applies until 30 June 2025
Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule
5. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.
The decisions were as follows:
|
Chemical name |
Presentation; |
Current |
New |
Principal Supply brand (Supplier) |
Date of listing |
Principal Supply Status date |
|---|---|---|---|---|---|---|
|
Fludrocortisone acetate |
Tab 100 mcg; 100 tablet bottle |
$14.32 |
$11.46 |
Florinef (Aspen) |
1 July 2022 |
1 December 2022 |
|
Oxytocin with ergometrine |
Inj 5 IU with ergometrine maleate 500 mcg per ml, 1ml; 5 ampoule pack |
$30.00 |
$32.40 |
Syntometrine (Max Health) |
1 July 2022 |
1 December 2022 |
6. Tenders awarded to Pharmaceuticals where at least one other brand is listed.
The decisions were as follows:
|
Chemical name |
Presentation; |
Current |
New |
Principal Supply brand (Supplier) |
Date of listing |
Principal Supply Status date |
Brand |
|---|---|---|---|---|---|---|---|
|
Atazanavir sulphate |
Cap 150 mg; 60 capsule blister pack bottle |
$141.68 |
$85.00 |
Atazanavir Mylan (Viatris) |
1 December 2022 |
1 February May 2023 |
Teva (Teva) |
|
Atazanavir sulphate |
Cap 200 mg; 60 capsule blister pack |
$188.91 |
$110.00 |
Atazanavir Mylan (Viatris) |
1 December 2022 |
1 February May 2023 |
Teva (Teva) |
|
Bisacodyl1 |
Tab 5 mg; 200 tablet blister pack |
$5.80 |
$5.80 |
Bisacodyl Viatris (Viatris) |
1 August 2022 |
1 January 2023 |
Pharmacy Health (API Consumer Brands) |
|
Levomepromazine hydrochloride |
Inj 25 mg per ml, 1 ml ampoule; 10 ampoule pack |
$33.50 |
$24.48 |
Wockhardt (Max Health) |
1 November 2022 |
1 April 2023 |
Nozinan (Sanofi) |
|
Liquid paraffin with white soft paraffin |
Oint liquid paraffin 50% with white soft paraffin 50%; 500 g tub OP |
$5.35 |
$4.94 |
White Soft Liquid Paraffin AFT (AFT) |
1 December 2022 |
1 May 2023 |
healthE (Jaychem) |
|
Paracetamol |
Oral liq 120 mg per 5 ml; 200 ml bottle |
$5.45 (per 1,000 ml) |
$3.98 |
Paracetamol (Ethics) (Multichem NZ) |
1 January 2023 |
1 June 2023 |
Paracare (API Consumer Brands) |
|
Paracetamol |
Oral liq 250 mg per 5 ml; 200 ml bottle |
$6.25 (per 1,000 ml) |
$3.35 |
Pamol (Aspen Pharma) |
1 November 2022 |
1 April 2023 |
Paracare Double Strength (API Consumer Brands) |
|
Sodium cromoglicate |
Eye drops 2%; 10 ml dropper bottle OP |
$1.79 (per 5 ml) |
$2.62 |
Allerfix (Teva) |
1 October 2022 |
1 March 2023 |
Rexacrom (Rex Medical) |
|
Thiamine hydrochloride |
Tab 50 mg; 100 tablet bottle |
$7.09 |
$4.65 |
Thiamine multichem (Multichem) |
1 November 2022 |
1 April 2023 |
Max Health (Max Health) |
|
1Stock is expected to become availble within August, a 1 August 2022 Pharmaceutical Schedule listing date has been applied to enable subsidised dispensing of this product within August. |
|||||||
See table 8 below for changes to section B of the Pharmaceutical Schedule in relation to bortezomib.
Hospital Pharmaceutical tenders – Section H of the Pharmaceutical Schedule.
7. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.
The decisions were as follows:
|
Chemical name |
Presentation; |
Current |
New |
Principal Supply brand (Supplier) |
DV limit |
Date of listing |
Principal Supply Status date |
|---|---|---|---|---|---|---|---|
|
Fludrocortisone acetate |
Tab 100 mcg; 100 tablet bottle |
$14.32 |
$11.46 |
Florinef (Aspen) |
5% |
1 July 2022 |
1 Decemeber 2022 |
|
Oxytocin with egometrine |
Inj 5 IU with ergometrine maleate 500 mcg per ml, 1ml; 5 ampoule pack |
$30.00 |
$32.40 |
Syntometrine (Max Health) |
5% |
1 July 2022 |
1 December 2022 |
8. Tenders awarded to Pharmaceuticals where at least one other brand is listed.
The decisions were as follows:
|
Chemical name |
Presentation; |
Current pack price |
New pack price |
Principal Supply brand (Supplier) |
DV Limit |
Listing date |
Principal Supply Status date |
Brand |
|---|---|---|---|---|---|---|---|---|
|
Atazanavir sulphate |
Cap 150 mg; 60 capsule blister pack bottle |
$141.68 |
$85.00 |
Atazanavir Mylan (Viatris) |
5% |
1 December 2022 |
1 February May 2023 |
Teva (Teva) |
|
Atazanavir sulphate |
Cap 200 mg; 60 capsule blister pack |
$188.91 |
$110.00 |
Atazanavir Mylan (Viatris) |
5% |
1 December 2022 |
1 February May 2023 |
Teva (Teva) |
|
Bisacodyl2 |
Tab 5 mg; 200 tablet blister pack |
$5.80 |
$5.80 |
Bisacodyl Viatris (Viatris) |
5% |
1 August 2022 |
1 January 2023 |
Pharmacy Health (API Consumer Brands) |
|
Bortezomib3 |
Inj 3.5 mg; 1 vial pack |
$105.00 |
$74.93 |
DBL Bortezomib (Pfizer) |
5% |
1 December 2022 |
1 May 2023 |
Bortezomib Dr Reddy’s (Dr Reddy’s) |
|
Levomepromazine hydrochloride |
Inj 25 mg per ml, 1 ml ampoule; 10 ampoule pack |
$33.50 |
$24.48 |
Wockhardt (Max Health) |
5% |
1 November 2022 |
1 April 2023 |
Nozinan (Sanofi) |
|
Liquid paraffin with white soft paraffin |
Oint liquid paraffin 50% with white soft paraffin 50%; 100 g tube |
$1.97 |
$1.84 |
White Soft Liquid Paraffin AFT (AFT) |
5% |
1 December 2022 |
1 May 2023 |
healthE (Jaychem) |
|
Paracetamol4 |
Oral liq 120 mg per 5 ml; 200 ml bottle |
$5.45 (per 1,000 ml) |
$3.98 |
Paracetamol (Ethics) (Multichem NZ) |
20% |
1 January 2023 |
1 June 2023 |
Paracare (API Consumer Brands) |
|
Paracetamol5 |
Oral liq 250 mg per 5 ml; 200 ml bottle |
$6.25 (per 1,000 ml) |
$3.35 |
Pamol (Aspen Pharma) |
20% |
1 November 2022 |
1 April 2023 |
Paracare Double Strength (API Consumer Brands) |
|
Sodium cromoglicate |
Eye drops 2%; 10 ml dropper bottle |
$1.79 (per 5 ml) |
$2.62 |
Allerfix (Teva) |
5% |
1 October 2022 |
1 March 2023 |
Rexacrom (Rex Medical) |
|
Thiamine hydrochloride |
Tab 50 mg; 100 tablet bottle |
$7.09 |
$4.65 |
Thiamine multichem (Multichem) |
5% |
1 November 2022 |
1 April 2023 |
Max Health (Max Health) |
|
2 Stock is expected to become availble within August, a 1 August 2022 Pharmaceutical Schedule listing date has been applied to enable dispensing of this product within August. 3The price and subsidy of bortezomib (PCT only – Specialist) in Section B of the Pharmaceutical Schedule will also be amended to the above price from 1 December 2022. The subsidy of bortezomib inj 1 mg for ECP in Section B of the Pharmaceutical Schedule will be amended from $31.20 per 1 mg to $22.26 per 1 mg from 1 December 2022. Bortezomib Dr Reddy’s inj 3.5 mg vial will be delisted from 1 May 2023. 4The following presentations will also be delisted from 1 June 2023: “Paracetamol oral liq 120 mg per 5 ml – 100 ml bottle and “Paracetamol oral liq 120 mg per 5 ml – 500 ml bottle” 5The following presentations will also be delisted from 1 April 2023: “Paracetamol oral liq 250 mg per 5 ml – 100 ml bottle and “Paracetamol oral liq 250 mg per 5 ml – 500 ml bottle |
||||||||
Tender declines - Products where no tender is to be awarded for Principal Supply Status
Pharmac has resolved not to award tenders for Principal Supply Status for the following products listed in the 2021/22 Invitation to Tender, dated 1 November 2021.
|
Chemical name |
Line item |
|---|---|
|
Adenosine |
Inj 3 mg per ml, 2 ml vial |
|
Levodopa with benserazide |
Cap 100 mg with benserazie 25 mg |
|
Levodopa with benserazide |
Cap 200 mg with benserazide 50 mg |
|
Levodopa with benserazide |
Cap 50 mg with benserazide 12.5 mg |
|
Levodopa with benserazide |
Cap long-acting 100 mg with benserazide 25 mg |
|
Levodopa with benserazide |
Tab dispersible 50 mg with benserazide 12.5 mg |
|
Levomepromazine |
Tab 100 mg |
|
Levomepromazine |
Tab 25 mg |
|
Levomepromazine |
Tab 5 mg – 10 mg |
|
Temozolomide |
Cap 100 mg |
|
Temozolomide |
Cap 140 mg |
|
Temozolomide |
Cap 20 mg |
|
Temozolomide |
Cap 250 mg |
|
Temozolomide |
Cap 5 mg |
For products included in the 2019/20, 2020/21 or 2021/22 Invitation to Tender where no announcement has yet been made, either a decision is still pending or is provisional, subject to the product gaining market approval and being available to supply, and subject to Pharmac Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made.
If you have any queries regarding this notification, please contact Pharmac on 0800 66 00 50.